ACAD has a billion dollar+ drug sure to be approved in PDP--the FDA is not requiring a second Phase III-- and very likely to work in ADP, a much larger market. Also, the drug had great efficacy in a Phase II trial in schizophrenia, a huge market. No one expected the Phase III trial to succeed, except me and Jason Napodano. LOLOL After two failed Phase III's, everyone gave up the company and the drug for dead. I bought my position at $1.29.
CLDX is a great company. The key value driver may turn out to be CDX-1127. If CDX-1127 is successful or shows promise at all AND it can be combined with the PD-1 inhibitors, then the sky is the limit. I was surprised to hear on the presentation at Jefferies that we will have data on CDX-1135 before the end of the year. CLDX must have gotten some enrollees in the trial. (Personally, I don't expect much from the Rindo + Avastin combo trial.)